CAY10499

CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities[1][2][3][4].

Product Specifications

CAS Number

[359714-55-9]

Product Name Alternative

MAGL-IN-5

UNSPSC

12352005

Target

FAAH; Influenza Virus; MAGL; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/magl-in-5.html

Concentration

10mM

Purity

99.58

Solubility

DMSO : 100 mg/mL

Smiles

O=C(OCC1=CC=CC=C1)NC2=CC=C(N3C(OC(OC)=N3)=O)C=C2C

Molecular Formula

C18H17N3O5

Molecular Weight

355.34

References & Citations

[1]Muccioli GG, et al. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem. 2008 Nov 3;9 (16) :2704-10. |[2]Granchi C, et al. 4-Aryliden-2-methyloxazol-5 (4H) -one as a new scaffold for selective reversible MAGL inhibitors. J Enzyme Inhib Med Chem. 2016;31 (1) :137-46.|[3]Baek YB, et al. Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus. Signal Transduct Target Ther. 2022 Oct 17;7 (1) :367.|[4]Zhuan Q, et al. Cytoplasm lipids can be modulated through hormone-sensitive lipase and are related to mitochondrial function in porcine IVM oocytes. Reprod Fertil Dev. 2020 Apr;32 (7) :667-675.